Eyetech Pharmaceuticals
Biopharmaceutical company that specializes in novel therapeutics to treat diseases of the eye.
Launch date
Market cap
-
Enterprise valuation
€395—592m (Dealroom.co estimates Aug 2001.)
New York City New York (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $150k | Series A | |
$34.7m | Series B | ||
* | $109m | Series C | |
$54.2m | Series C | ||
$25.0m | Series D | ||
| N/A | N/A | IPO | |
| N/A | $250k | Grant | |
N/A | Acquisition | ||
| Total Funding | €203m | ||